Ozempic and Wegovy prescriptions increase in Q1 2025?
Ozempic and Wegovy prescriptions increase in Q1 2025?
7% or above
No
7% or above
No
10% or above
No
10% or above
No
12% or above
No
12% or above
No
2 more
Market Rules
5% or above
If prescriptions made for weight loss drugs (using semaglutide and tirzepatide) grow by 5% in Q1 2025, then the market resolves to Yes. Outcome verified from IQVIA.
The number of weight drug prescriptions at the end of Q1 2025 has not been sent to the Kalshi team yet.
Timeline and payout
Market openJan 15, 2025 · 10:00am EST
Market closedApr 25, 2025 · 2:00pm EDT
Paid outMay 11, 2025 · 11:00am EDT
SeriesKXWEIGHTDRUGSQ
EventKXWEIGHTDRUGSQ-1-25
MarketKXWEIGHTDRUGSQ-1-25-5
Insider trading is prohibited
The following are prohibited from trading this contract:
- Persons who are employed by any of the Source Agencies are not permitted to trade on the Contract.
- Persons who hold any material, non-public information on the Underlying are not permitted to trade on the Contract.
About
Ozempic and Wegovy are poised for record-breaking sales in 2023 and going into 2024, as demand for these medications skyrockets. Will the surge in prescriptions continue, or will the market eventually reach saturation point?